Short answer
Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). VenRock surrendered 1,000,000 common shares for no consideration, reducing immediately outstanding shares.
Korro Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- VenRock surrendered 1,000,000 common shares for no consideration, reducing immediately outstanding shares
- Korro issued immediately exercisable pre-funded warrants for 1,000,000 shares at a $0.001 exercise price with no expiration
- Exchange shifts VenRock ownership from common stock into warrants, potentially preserving future dilution
- Post-exchange capital structure: 13,725,646 shares outstanding and warrants for 4,148,836 shares
- 9.99% beneficial-ownership cap limits immediate warrant exercise but can be adjusted with 61 days’ notice
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
- Filing signals earnings disclosure; investors should review Exhibit 99.1 for revenue, cash runway, operating loss, and pipeline updates
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $18.9M, improving from $25.8M; six-month loss $38.5M versus $49.2M
- Cash, equivalents and marketable securities $137.9M, funding operations into the second half of 2028
- KRRO-121 received EMA Orphan Drug Designation and remains targeted for first-in-human trials in second half 2026
- KRRO-111 nominated for AATD after preclinical results showing over 90% editing and approximately 90% restored functional AAT
- Collaboration revenue fell to $0 from $1.5M as Novo Nordisk partnership remained paused for 12 months beginning November 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Korro Bio, Inc. 8-K filings
Get the next KRRO 8-K as it lands
Follow KRRO for push alerts, or ask the research agent what this filing means.